IND Safety Reports: Industry Praises FDA’s Move Towards Less Unblinding, But Wants More Flexibility
Executive Summary
Sponsors are pleased with agency’s embrace of the ‘trigger’ approach to unblinding for safety reporting in new guidance but continue to want additional ways to keep the blind. Industry also raised concerns that parts of the guidance contradict international regulators.
You may also be interested in...
US FDA Is No Longer ‘Getting Crap’ From Sponsors In IND Safety Reports, Temple Says
FDA’s Robert Temple says he is gratified by the way companies have implemented the agency’s guidance on IND safety reporting. Merck, AbbVie and Janssen representatives discuss issues with unblinding data and the value of an aggregate analysis at DIA’s annual meeting.
IND Safety Analysis Requires Broader Unblinding Of Reports, US FDA Advises
A draft guidance from the US Food and Drug Administration is recommending that pharmaceutical sponsors develop safety assessment committees that would review safety information in a drug development program and determine what information must be reported in an investigational new drug (IND) safety report.
FDA’s Authority Looks Safe From Judicial Interference Following Supreme Court Abortion Pill Arguments
The agency's and the pharma industry’s worst fears – that a potential ruling in the mifepristone case might usurp the FDA’s scientific authority and throw the stability of the US drug approval process into question – seem unlikely to materialize as the majority of the Supreme Court justices signal the Alliance for Hippocratic Medicine lacks standing to sue.